Moxifloxacin ophthalmic solution - Zion Therapeutics

Drug Profile

Moxifloxacin ophthalmic solution - Zion Therapeutics

Alternative Names: Zimoxin

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zion Therapeutics
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Endophthalmitis

Most Recent Events

  • 22 Aug 2017 Chemical structure information added
  • 07 Aug 2017 Zion Therapeutics plans a phase II/III trial for Endophthalmitis (Prevention) in USA (Intracameral, Injection) (NCT03244072)
  • 04 Aug 2017 Clinical trials in Endophthalmitis (Prevention) in USA (Intraocular) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top